America's Growth Leaders Cytek Biosciences has been recognized by TIME as one of America’s Growth Leaders of 2026. Presented in partnership with global data firm Statista, the ranking recognizes the top-performing publicly listed companies in the United States that have demonstrated exceptional growth, financial stability, and stock performance over the past five years. FREMONT, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) today announce ...

Core Insights - Cytek Biosciences, Inc. has been recognized in TIME's 2026 list of America's Growth Leaders, highlighting its exceptional growth, financial stability, and stock performance over the past five years [1][5] - The inclusion in this list signifies Cytek's strong financial foundation and sustained business expansion, particularly in delivering innovative cell analysis solutions [2][5] Company Overview - Cytek Biosciences specializes in high-parameter cell analysis solutions, utilizing its patented Full Spectrum Profiling™ (FSP®) technology to enhance the precision and sensitivity of cell analysis [6] - The company aims to make high-parameter cell analysis more accessible and cost-effective for laboratories of all sizes, addressing urgent challenges in health and scientific research [3][4] Industry Impact - Cytek's FSP systems are referenced in over 3,200 peer-reviewed publications, demonstrating their significant impact on global research [4] - The company's innovations support advancements in cancer research, cell and gene therapies, vaccine development, and responses to emerging diseases [3][4]

Core Insights - Cytek Biosciences, Inc. has been awarded the title of Drug Discovery Solution of the Year for its Cytek Muse Micro cell analyzer at the 2025 BioTech Breakthrough Awards, recognizing its innovative contributions to the life sciences and biotechnology sectors [1][3][10] Company Overview - Cytek Biosciences is a leading company in cell analysis solutions, focusing on high-resolution, high-content, and high-sensitivity cell analysis through its patented Full Spectrum Profiling™ (FSP) technology [5] - The company is headquartered in Fremont, California, and has a global presence with offices and distribution channels [5] Product Highlights - The Cytek Muse Micro cell analyzer enhances the original Guava Muse system, offering a compact, cost-effective, and multifunctional platform that simplifies flow cytometry while maintaining accuracy and versatility [2][4] - Applications of the Muse Micro system include cell counting, cell health and viability assessment, apoptosis, immunophenotyping, immune cell monitoring, and fluorescent protein analysis [2] Market Impact - The Muse Micro system aims to democratize access to sophisticated cell analysis, making it more accessible for smaller labs and resource-limited facilities, which traditionally faced barriers due to the complexity and cost of traditional flow cytometry systems [3][4]

Core Insights - Cytek Biosciences, Inc. is launching a two-part research support initiative to enhance accessibility to cell analysis amid reduced government funding and global economic challenges [1][2][3] Group 1: Initiative Details - The first phase involves awarding a three-laser Cytek Northern Lights™ flow cytometer, which utilizes Full Spectrum Profiling™ technology for versatile assays [2][3] - The second phase will introduce a grant program for funding eligible research projects, assessed through a merit-based process overseen by a scientific advisory board [3] Group 2: Collaboration and Impact - Cytek's initiatives are part of an ongoing collaboration with the International Society for Advancement of Cytometry (ISAC) to improve access to advanced cytometry tools globally [4] - A previous donation of a Cytek Northern Lights™ flow cytometer to a lab in Argentina exemplifies the impact of collaboration in empowering scientists in underserved communities [4] Group 3: Company Commitment - Cytek is dedicated to democratizing access to flow cytometry, ensuring that labs of all sizes and budgets can utilize advanced tools for cellular insights [5] - The company emphasizes the importance of community engagement alongside technological innovation to benefit the entire scientific community [5][7]

Core Insights - Cytek Biosciences, Inc. will report its financial results for Q3 2025 on November 5, 2025, after market close, followed by a conference call to discuss the results and outlook [1] Company Overview - Cytek Biosciences is a leading company in cell analysis solutions, utilizing its patented Full Spectrum Profiling™ (FSP) technology to deliver high-resolution and high-sensitivity cell analysis tools [2] - The company's product offerings include FSP instruments such as Cytek Aurora™, Northern Lights™, and Cytek Orion™, along with various reagents and software, providing a comprehensive suite of solutions for customers [2] - Cytek is headquartered in Fremont, California, with a global presence through offices and distribution channels [2] Product Usage - Cytek's products are intended for research use only, with specific exceptions for clinical use in China and the European Union for certain systems and reagents [3] Information Distribution - The company utilizes multiple channels, including its website, LinkedIn, and X account, to disseminate material information and comply with disclosure obligations under Regulation FD [4]

Core Insights - Cytek Biosciences has relocated its European headquarters to a new facility in Amsterdam's Life Sciences District, reflecting its commitment to the EMEA region and enhancing service for customers [1][4] - The new site has increased the company's footprint by over 40% and includes a dedicated customer service and training center, providing hands-on training for researchers [2] - The success of Cytek's reagent business is a major driver for this expansion, with the company transitioning warehouse operations in-house to improve operational efficiency and quality control [3] Company Overview - Cytek Biosciences is a leading cell analysis solutions company that utilizes its patented Full Spectrum Profiling™ (FSP) technology to deliver high-resolution and high-sensitivity cell analysis tools [5] - The company's product offerings include various systems and technologies designed to enhance multiplexing capabilities and provide comprehensive solutions for researchers [5] - Cytek's products are primarily for research use, with certain systems available for clinical use in specific regions [6] Strategic Importance - Europe is identified as a key region for Cytek's global growth, and the new Amsterdam facility is expected to enhance the company's capabilities in delivering solutions and services across the EMEA region [4][15] - The expansion aims to support scientific understanding and accelerate data-driven decision-making, fostering innovation within the industry [4]

Core Insights - Cytek Biosciences, a leader in spectral flow cytometry, is set to showcase its advanced solutions at two major industry events, emphasizing the growing demand for deeper cellular insights in cancer research and diagnostics [1][4] Company Overview - Cytek Biosciences specializes in high-resolution, high-content, and high-sensitivity cell analysis tools, utilizing its patented Full Spectrum Profiling™ (FSP) technology [8] - The company's FSP systems have been referenced in over 2,800 peer-reviewed publications, indicating widespread acceptance and application in the research community [2] Technology and Innovation - Cytek's Full Spectrum Profiling™ technology allows for the profiling of more than 40 markers in a single tube, significantly enhancing efficiency and reducing analysis time [7] - The integration of spectral flow cytometry with machine learning is being explored to simplify data analysis and reduce technician workload, as demonstrated in workshops at upcoming conferences [4][6] Industry Events - The European Society for Clinical Cell Analysis (ESCCA) 2025 Conference will take place from September 17 to September 20, 2025, in Montpellier, France, focusing on clinical applications in various fields [3] - The ICCS Annual Meeting & Course will be held from September 28 to September 30, 2025, in Philadelphia, bringing together professionals to advance knowledge in clinical cytometry [5] Leadership and Expertise - Dr. Wenbin Jiang, CEO of Cytek, highlighted the advantages of spectral flow cytometry in enabling laboratories to achieve more with less, thereby allowing scientists to focus on high-skill tasks [7] - Workshops led by experts like Dr. Joseph C. Lownik and Dr. Paul K. Wallace will present innovative approaches to using spectral flow cytometry for accurate diagnosis of leukemia and lymphoma [4][6]

Financial Data and Key Metrics Changes - Total revenue for Q2 2025 was $45.6 million, a decrease of $1 million or 2.2% compared to Q2 2024, primarily due to lower product revenue in EMEA and APAC, partially offset by strong growth in service revenue worldwide, which grew by 18% [8][22] - Product revenue decreased by 9% year-over-year, driven by a significant decline in EMEA, while US product revenue increased by 2% [22][23] - GAAP gross profit was $23.9 million, a 6% decline versus the prior year, with a gross profit margin of 52% compared to 55% in the prior year quarter [25] Business Line Data and Key Metrics Changes - Recurring revenue businesses reached 32% of trailing twelve-month sales in Q2, growing by 16% year-over-year, with service and reagent revenue each increasing by 18% [9][10] - FSP unit volume grew by 3% in Q2, led by AURORA analyzers, with particular strength in the US showing 10% year-over-year growth [10][11] - Service revenue continued to deliver strong growth of 18% in Q2 versus the prior year and 21% for the first half [24] Market Data and Key Metrics Changes - Total US revenue was up 7% over the prior year, driven by service and reagents, while EMEA revenue declined by 11% due to lower instrument sales [11][24] - APAC sales declined following a strong Q1, primarily due to longer sales cycles, but showed solid growth on a year-over-year basis [12] - The rest of the world region, including Canada and Latin America, delivered single-digit percentage revenue growth compared to last year's second quarter [12] Company Strategy and Development Direction - The company aims to solidify its market leadership in next-gen cell analysis solutions through innovation and differentiated offerings, including the launch of the Cytec Aurora EVO system [17][31] - The focus remains on expanding the installed base globally, which is expected to drive growth in instrument revenue and sustainable recurring revenue in service and reagent businesses [31][32] - The company is open to M&A opportunities that have synergy potential, while also investing in organic growth through its reagent and service segments [48][50] Management's Comments on Operating Environment and Future Outlook - Management noted that the capital equipment spending environment remains challenging, particularly in the academic and government sectors, but expects a recovery over time [14][32] - The company narrowed its full-year 2025 revenue guidance to a range of $196 million to $205 million, reflecting overall growth of -2% to +2% compared to 2024 [29] - Management expressed confidence in the growth of recurring revenue streams and the core business despite the current market challenges [29][30] Other Important Information - The installed instrument base grew by 146 units in Q2, bringing the total to 3,295 units, indicating steady expansion across a diverse customer base [15][16] - The company reported a positive free cash flow of $900,000 in Q2, despite stock repurchases totaling $4.5 million [28] Q&A Session Summary Question: How is the Flow Cytometry market performing and are there any competitive concerns? - Management indicated that the overall flow cytometry market is experiencing a downturn due to funding challenges, but the company continues to grow its core business and unit volume [34][35] Question: How comfortable is the company with the second half guidance? - Management expects stronger performance in the second half, driven by recurring revenue growth, while capital spending is anticipated to be back-end weighted [40][41] Question: Is the company open to M&A opportunities? - Management confirmed openness to M&A, focusing on opportunities with synergy potential in existing markets or adjacencies [48][49] Question: What is the expected contribution from new products like AURORA EVO? - AURORA EVO is expected to be a significant contributor to revenue, supporting margins, while MUSE Micro is not expected to have a major impact on margins [64][65] Question: What are the drivers of service revenue growth? - Service revenue growth is driven by the installed base, with expectations that this growth will continue based on past performance [66][67]

Core Viewpoint - Cytek Biosciences, Inc. will report its financial results for Q2 2025 on August 6, 2025, followed by a conference call to discuss the results and business outlook [1]. Company Overview - Cytek Biosciences is a leading company in cell analysis solutions, utilizing its patented Full Spectrum Profiling™ (FSP) technology to deliver high-resolution and high-sensitivity cell analysis tools [2]. - The company's product offerings include FSP instruments such as Cytek Aurora™, Northern Lights™, and Cytek Orion™, along with various reagents, software, and services [2]. - Cytek is headquartered in Fremont, California, with a global presence through offices and distribution channels [2]. Product Usage - Cytek's products are intended for research use only, with specific exceptions for clinical use in China and the European Union for certain systems and reagents [3]. Information Distribution - The company utilizes its website, LinkedIn, and X (formerly Twitter) for distributing material information and compliance with disclosure obligations under Regulation FD [4].

Summary of Cytek Biosciences (CTKB) FY Conference Call - June 11, 2025 Company Overview - **Company**: Cytek Biosciences (CTKB) - **Industry**: Biotechnology, specifically in flow cytometry and related services Key Points and Arguments Business Segmentation and Performance - The business is divided into two main segments: service and instrument sales, with service showing consistent growth linked to the installed base of instruments [3][4][22] - The reagent business has shown steady growth, with improvements in execution and delivery times contributing to confidence in future performance [4][22] - The Asia Pacific and rest of the world markets are experiencing good growth, contrasting with pressures on academic funding in the U.S. and Europe [5][6][32] Market Conditions and Guidance - Guidance for the year is bracketed between a decline of 2% and growth of 5%, reflecting uncertainty in academic funding and purchasing decisions [6][7] - The flow cytometry market overall saw a decline of 2% in Q1, with Cytek outperforming this due to a growing installed base and product innovation [10][12][13] - The company expects to continue outpacing the market due to its focus on full spectrum profiling and strong product offerings [14] Service Business Growth - The service business is projected to grow faster than instrument sales, potentially becoming a larger portion of overall revenue [22][23] - Recurring revenue, including services and reagents, currently accounts for about 31% of total revenue, with aspirations to increase this to the 40% range in the future [22][30] Regional Insights - Cytek has established a strong presence in China, benefiting from government stimulus programs and becoming a recognized brand in the market [32][33] - The company ranks as the third supplier in China, indicating significant growth potential in this region [32] Cost Structure and Profitability - Approximately 75% to 80% of incremental revenue contributes to EBITDA, with gross margins expected to improve from 55% towards 60% [38][40] - The company has a fixed versus variable cost structure that allows for significant margin expansion as revenue grows [39][42] Technological Advancements - The Cytek Cloud platform has gained traction with 18,000 users, enhancing customer engagement and providing a competitive edge through data management and analysis capabilities [43][44][48] - The platform allows for efficient panel design and reagent purchasing, which is expected to drive service revenue growth [44][48] Investor Insights - The company emphasizes its positive EBITDA and cash flow generation, distinguishing itself from other small-cap tools companies [50] - Recent product innovations, such as the new AURORA analyzer, have received positive feedback, suggesting strong future sales potential [50][51] Additional Important Content - The company is managing tariff impacts through regional manufacturing strategies, with minimal expected effects on gross margins [34][36] - The service contracts are crucial for maintaining high instrument utilization, which is essential for core labs operating as businesses [23][26]